Efficacy, safety and immunogenicity of biosimilars in inflammatory bowel diseases: A systematic review

L Martelli, L Peyrin-Biroulet - Current Medicinal Chemistry, 2019 - ingentaconnect.com
Background: Anti-tumor necrosis factor (anti-TNF) monoclonal antibodies have
revolutionized the treatment of inflammatory bowel diseases (IBD). However, because of …
被引用次数：26 相关文章

Efficacy, Safety and Immunogenicity of Biosimilars in Inflammatory Bowel Diseases: A Systematic Review.

L Martelli, L Peyrin-Biroulet - Current Medicinal Chemistry, 2019 - europepmc.org
Background Anti-tumor necrosis factor (anti-TNF) monoclonal antibodies have
revolutionized the treatment of inflammatory bowel diseases (IBD). However, because of …

Efficacy, Safety and Immunogenicity of Biosimilars in Inflammatory Bowel Diseases: A Systematic Review

L Martelli, L Peyrin-Biroulet - Current medicinal chemistry, 2019 - pubmed.ncbi.nlm.nih.gov
Background Anti-tumor necrosis factor (anti-TNF) monoclonal antibodies have
revolutionized the treatment of inflammatory bowel diseases (IBD). However, because of …